Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) CFO Christopher Cline sold 50,508 shares of Travere Therapeutics stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $3,148,668.72. Following the sale, the chief financial officer directly owned 87,508 shares of the company’s […]

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) Director James Wilson sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $110.69, for a total transaction of $1,106,900.00. Following the completion of the transaction, the director directly owned 1,064,543 shares of the […]

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director owned 168,640 shares in the company, […]

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $35.12, for a total transaction of $649,720.00. Following the sale, the chief executive officer owned 235,244 shares of the company’s stock, […]